News

The new collaboration agreement, designated OPeRA (Organ Protection & Replacement Institute), includes pre-clinical research and development programs as well as clinical phase II programs, providing NeuroVive with access

The trial is designed to evaluate the long-term safety and efficacy of GCS-100 in patients who completed the initial 12-week Phase II study (GCS-100-CS-4002). In the 4003 extension

Both the companies have not disclosed the financial terms of the agreement. Genmab chief executive officer Jan van de Winkel said the company is happy to enter its

The product, which is available in the 5mg and 10mg strengths, is indicated for the treatment of narcolepsy and attention deficit disorder with hyperactivity. The company received final

The partnership employs KineMed’s new dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways. KineMed president, co-founder and chief science officer

The company said that the new licensed patents include protection for human therapeutic uses of NR and build upon the patents licensed from Dartmouth in 2012 for other

In Canada, standard review takes 18 months or more and priority review, which is granted to promising medicines that address life-threatening or severely debilitating conditions, shortens the review

The company said that results were also observed in patients with ALK+ NSCLC who entered the trial with brain metastases. Seoul National University Hospital lead investigator Dong-Wan Kim

The European Commission has also granted orphan drug designation for HETLIOZ to treat Non-24 in blind people with no light perception. In January 2014, HETLIOZ was approved by